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Integration of comprehensive women’s health programmes into health 
systems: cervical cancer prevention, care and control in Rwanda
Agnes Binagwaho,a Fidele Ngabo,a Claire M Wagner,b Cathy Mugeni,a Maurice Gatera,c Cameron T Nuttd &  
Sabin Nsanzimanac
Background
Cervical cancer is among the most common cancers affecting 
women around the world.1 The estimated annual number of 
deaths from cervical cancer – 275 000 – is similar to the annual 
number of maternal deaths in childbirth.1,2 As is the case with 
many other diseases, cervical cancer disproportionately affects 
the poorest populations. Overall, 77% of new cases of cervical 
cancer3 and 88% of deaths attributed to such cancer1 occur in 
the developing world, where 95% of women have never been 
screened for the disease.4
With adequate screening and early detection, the pro-
gression of precancerous cervical lesions can be completely 
arrested in most cases, and cervical cancers in an early stage 
are highly treatable. As a result, high-income countries with 
good levels of screening have seen dramatic declines in the 
incidence and mortality of cervical cancer in recent decades.5
Nearly all cases of cervical cancer are caused by the 
human papillomavirus (HPV).6 Two prophylactic HPV vac-
cines can each prevent up to 70% of cervical cancer cases 
and perhaps also some cancers of the vulva, vagina, anus, 
penis and oropharynx that are related to HPV.6 These vac-
cines are being rolled out in a growing number of countries 
on six continents and, with high coverage, could cause 
massive reductions in the incidence of cervical cancer in 
coming decades.6
Rwanda – a small, landlocked nation in East Africa with 
a population of 10.4 million – is the first country in Africa to 
develop and implement a national strategic plan for cervical 
cancer prevention, care and control. Rwanda is well posi-
tioned to tackle some “high-burden” cancers, as its integrated 
response to infectious diseases has resulted in steep declines 
in premature mortality over the past decade.7 In the present 
paper, we describe Rwanda’s strategic plan for cervical cancer 
and its integration into the national health system; report the 
plan’s progress to date; and offer recommendations to other 
countries at similar decision points in the formulation of na-
tional health policies and the initiation of efforts to combat 
cervical cancer.
Epidemiological imperative
Eastern Africa has one of the highest levels of mortality 
among cases of cervical cancer in the world and women in 
the region have a 2.7% cumulative probability of death from 
cervical cancer.8 According to the age-standardized estimates 
of the International Agency for Research on Cancer and the 
World Health Organization, in 2008 Rwanda had 34.5 cases of 
cervical cancer and 25.4 deaths attributable to cervical cancer 
per 100 000 inhabitants.9 At the time, the incidence of cervical 
cancer among Rwanda’s women appeared to be higher than 
the combined incidences of breast, liver and stomach cancer.9 
Female life expectancy at birth in Rwanda has climbed steadily 
in recent years – to 61 years in 201110 – after stagnating between 
29 and 35 years in the period surrounding the genocide in 
1994.11 The annual incidence of cervical cancer would therefore 
be expected to rise in the absence of nationwide interventions 
against the disease.
Problem Although it is highly preventable and treatable, cervical cancer is the most common and most deadly cancer among women in Rwanda.
Approach By mobilizing a diverse coalition of partnerships, Rwanda became the first country in Africa to develop and implement a national 
strategic plan for cervical cancer prevention, screening and treatment.
Local setting Rwanda – a small, landlocked nation in East Africa with a population of 10.4 million – is well positioned to tackle a number 
of “high-burden” noncommunicable diseases. The country’s integrated response to infectious diseases has resulted in steep declines in 
premature mortality over the past decade.
Relevant changes In 2011–2012, Rwanda vaccinated 227 246 girls with all three doses of the human papillomavirus (HPV) vaccine. Among 
eligible girls, three-dose coverage rates of 93.2% and 96.6% were achieved in 2011 and 2012, respectively. The country has also initiated 
nationwide screening and treatment programmes that are based on visual inspection of the cervix with acetic acid, testing for HPV DNA, 
cryotherapy, the loop electrosurgical excision procedure and various advanced treatment options.
Lessons learnt Low-income countries should begin to address cervical cancer by integrating prevention, screening and treatment into 
routine women’s health services. This requires political will, cross-sectoral collaboration and planning, innovative partnerships and robust 
monitoring and evaluation. With external support and adequate planning, high nationwide coverage rates for HPV vaccination and screening 
for cervical cancer can be achieved within a few years.
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Despite sustained economic growth 
since 2000, Rwanda remains one of 
the poorest countries in the world and 
does not have the financial flexibility to 
build its own independent programme 
against cervical cancer. Nearly half of 
the country’s health budget is externally 
financed.12 The national government 
recently had to decide what to do about 
cervical cancer in the face of many other 
competing health needs and financial 
constraints.
Point of departure: HPV 
vaccine
In 2009 – three years after an HPV 
vaccine was introduced in the United 
States of America – advocacy by Jean-
nette Kagame, the First Lady of Rwanda, 
led to technical meetings between the 
Rwandan Ministry of Health and Merck 
& Co., the manufacturer of the quad-
rivalent HPV vaccine Gardasil. These 
negotiations sparked a partnership for 
the national rollout of the HPV vaccine 
in Rwanda. Merck agreed to donate ap-
proximately 2 million doses of Gardasil 
over a period of three years and to guar-
antee concessional pricing of the vaccine 
to Rwanda and external funders thereaf-
ter. Simultaneously, the health ministry 
initiated the planning phase for a com-
prehensive national programme for cer-
vical cancer prevention, screening and 
treatment. A demonstrated readiness to 
integrate a vaccination for adolescents 
into Rwanda’s national immunization 
programme decreased the time required 
to formulate strategy and initiate imple-
mentation. By 2010 – before rolling out 
the HPV vaccine – Rwanda had already 
achieved coverage rates exceeding 93% 
of eligible subjects for vaccines against 
nine diseases, including the pneumo-
coccal conjugate vaccine.13 Following a 
national consultation, Rwanda elected to 
vaccinate all girls in grade 6 of primary 
school, for free, on three designated 
“health days” each year, beginning in 
2011.14 These “health days” are now used 
not only for HPV vaccination but also 
for disseminating essential adolescent 
health messages – to an otherwise hard-
to-reach age group – at regular intervals. 
Beginning in 2012, these “health days” 
have also been used for a nationwide 
campaign of deworming for 3.8 million 
children in primary schools. In 2012, 
the deworming coincided with the first 
HPV vaccine dose for the 2012 cohort. 
In October 2012, delivery of the third 
vaccine dose for the 2012 cohort was 
timed to overlap with another cam-
paign: Rwanda’s annual Maternal and 
Child Health Week. The latter campaign 
involves sensitization about hand hy-
giene and reproductive health, delivery 
of mebendazole, iron and folic acid to 
pregnant women, and the provision of 
vitamin A supplementation to children 
and breastfeeding women.
By enlisting teachers and village 
leaders in sensitization efforts and by 
mobilizing the country’s 45 000 com-
munity health workers to trace out-of-
school girls, the HPV vaccination pro-
gramme achieved a high coverage rate in 
its first year: 92 107 (93.2%) of the 98 792 
eligible girls identified in 2011 were fully 
vaccinated (Table 1).14 Two “catch-up” 
rounds of vaccination targeted girls 
who were in the third year of secondary 
school in 2012 or 2013. The aim was 
to ensure that all girls younger than 15 
years in 2011 had the opportunity to 
receive a full course of HPV vaccination. 
In 2012, the routine campaign targeting 
girls in grade 6 of primary school led to 
90 188 of the 93 243 eligible girls each 
receiving three doses, while 394 of 549 
out-of-school girls aged 12 years were 
also fully vaccinated. The corresponding 
“catch-up” campaign – targeting girls 
in the third year of secondary school – 
led to the full vaccination of 43 927 of 
45 361 eligible in-school girls and 630 
of 815 eligible out-of-school girls aged 
14 years. In total, therefore, 135 139 
(96.6%) of 139 968 eligible girls were 
fully vaccinated in 2012 (Table 1).
There has been concern that some 
countries that are eligible for support 
from the Global Alliance for Vaccines 
and Immunisation (GAVI) may lack 
sufficient capacity to plan adequately, 
manage cold chain deployment, navi-
gate the nuances of communication, 
achieve high coverage and mobilize 
partners to ensure financial sustain-
ability.15,16 Rwanda’s experience and 
success in scaling up access to HPV 
vaccine indicates that these concerns 
are largely unfounded. Halfway through 
the first year of Rwanda’s HPV vaccina-
tion programme, Merck dropped the 
price of the HPV vaccine by more than 
70% from its previous lowest price per 
dose – from 16.95 to 5.00 United States 
dollars.17 Following GAVI’s incorpora-
tion of the HPV vaccine into its routine 
funding portfolio in late 2012, further 
price reductions have been announced, 
with more expected in the near future.18 
Merck’s partnership helped to bridge 
the gap between Rwanda’s aspirations 
for the prevention of cervical cancer 
and the actions that the country was 
able to implement against the disease. 
Other private sector pharmaceutical 
and medical device companies have 
recently declared an interest in Rwanda’s 
programme against cervical cancer. In 
late 2011, for example, QIAGEN signed 
a memorandum of understanding with 
the Rwandan Ministry of Health and 
agreed to donate equipment and con-
sumables for HPV screening, beginning 
in 2013.
Continued efforts to engage the 
population in dialogue about the HPV 
vaccine will be essential if high coverage 
is to be sustained in Rwanda. As anti-
vaccine activism has begun to find its 
way – via the Internet and social media 
– into communities across Africa, the 
Rwandan Ministry of Health will main-
tain preparedness through campaigns of 
mass sensitization and communication 
with local leaders across the country.
Screening and diagnosis
In high-income countries, screening for 
cervical cancer is generally integrated 
into the annual consultations recom-
Table 1. Human papillomavirus vaccination coverage, Rwanda, 2011–2012
Coverage 2011 2012
Round 1 Round 2 Round 3 Round 1 Round 2 Round 3
No. of girls vaccinated
In schoola 91 752 89 704 88 927 137 147 134 645 134 115
Outside school 2 136 3 066 3 180 1 162 845 1 024
Overall 93 888 92 770 92 107 138 309 135 490 135 139
Cumulative coverage (%)b 95.0 93.9 93.2 98.8 96.8 96.6
a  The three rounds of vaccination in 2011 only covered girls who were in Grade 6 of primary school 
whereas the rounds in 2012 covered girls who were then in Grade 6 of primary school or the third year of 
secondary school.
b  The denominator for 2011: 98 792 eligible girls; denominator for 2012: 139 968 eligible girls.
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mended for women. However, in many 
low- and middle-income countries most 
women do not have access to such regu-
lar encounters with the primary-health-
care system. Fortunately, screening 
methods for cervical cancer are diverse 
and easily implemented. They include 
testing for HPV DNA, the Papanicolaou 
– or “pap smear”– test, visual inspection 
with acetic acid, colposcopy and biopsy. 
Precancerous lesions, or dysplasia, can 
take 10 to 20 years to develop into cervi-
cal cancer. Therefore, even though early 
detection is crucial, screening for cervi-
cal cancer can be effectively conducted 
at longer intervals than screening for 
breast cancer or other forms of cancer 
that progress more rapidly than cervical 
cancer.4 The costly and complex Papa-
nicolaou tests appear to be of similar 
sensitivity and specificity to the cheaper 
and simpler visual inspection with acetic 
acid, whereas colposcopy and biopsy 
require specialization. In the detection 
pathway developed by Rwanda and its 
partners, testing for HPV DNA is there-
fore followed by visual inspection with 
acetic acid and then, when necessary, by 
colposcopy and biopsy (Fig. 1).
Before the implementation of the 
national strategic plan for cervical 
cancer prevention, care and control, 
visual inspection of the cervix with 
acetic acid was offered sporadically at 
several public and private health facili-
ties across Rwanda. With the equipment 
and consumables donated by QIAGEN, 
Rwanda will now scale up access to a 
more diverse set of screening options 
for cervical cancer that will initially be 
offered in five district hospitals and 15 
health centres in these hospitals’ catch-
ment areas beginning in June 2013. If 
everything goes to plan, cervical cancer 
screening in Rwanda will be decentral-
ized to 30 public hospitals and nearly 
100 health centres by 2015. Between 
2013 and 2016, QIAGEN will donate 
250 000 assays and 29 machines for its 
careHPV DNA testing system, while 
the Rwandan government and other 
partners will finance the scale-up of 
visual inspection of the cervix with 
acetic acid. As it is predicted that 18 700 
of the donated careHPV assays will be 
used incorrectly or for repeat tests, it has 
been estimated that QIAGEN’s support 
will allow 231 300 Rwandan women to 
be tested for the DNA of the forms of 
HPV associated with cervical cancer.
Since December 2012, nurses and 
physicians performing the screening 
tests have been receiving intensive train-
ing. Eight national pathology trainers 
will be trained by the American Society 
for Clinical Pathology, and QIAGEN has 
already trained eight laboratory techni-
cians as trainers in reading the results of 
tests for HPV DNA and histopathology. 
Several of these 16 trainers will together 
train another 32 pathologists and labo-
ratory technicians by the end of 2013. 
The National Reference Laboratory in 
Kigali will receive technical support to 
assume full responsibility for diagnosing 
cervical cancer by 2015.
Starting in June 2013, at standard 
meetings with nurses in Rwanda’s 15 000 
villages, community health workers will 
be told the dates when a mobile team 
of one physician and two to four nurses 
will visit the local health centre for HPV 
screening over a three-day period. The 
community health workers will enroll 
women for free screening and then 
return the corresponding enrolment 
forms to the local health centre. The ages 
of the women enrolled will depend on 
whether they have been found infected 
with human immunodeficiency virus 
(HIV) – women known to be HIV-
positive and aged 30 to 50 years will be 
enrolled, as well as other women aged 35 
to 45 years. Nurses will then report to 
the district level, indicating the number 
of women enrolled for each screening 
day. These reports will allow the mobile 
teams to determine the quantity of re-
agents needed and the likely duration 
of the screening on each screening day. 
With this system, it is expected that ap-
proximately 360 women will be tested in 
a single day by each team. Each screened 
woman will be asked to stay at the health 
centre for a few hours, until the results of 
her test are available. While waiting, she 
will be educated about cervical cancer 
and other aspects of reproductive health.
Treatment and palliative 
care
The size, location and stage of a precan-
cerous or cancerous lesion determine 
the choice of treatment. The options 
include cryotherapy, the loop electrosur-
gical excision procedure (LEEP), laser 
surgery, hysterectomy, chemotherapy 
and radiation therapy. For women who 
receive cryotherapy or LEEP – two of the 
most common methods for treatment 
of early lesions in low-income settings 
– cure rates, with the recommended 
standard of care, approach 90%.19 Given 
Fig. 1. Cervical cancer screening and treatment in Rwanda, 2013
HIV-negative woman 
aged 35–45 years, 
recruited to health centre
HIV-positive woman aged 
30–50 years, recruited to 
health centre
Cryotherapy  
on same day, at 
health centre
Refer to hospital 
for LEEP
Refer for biopsy 
and advanced 
treatment
CareHPV test performed  
to detect  high-risk forms 
of HPV 
Rescreen in 7 years 
if HIV-negative and 
3 years if HIV-positive
VIA test performed 
on same day












HIV, human immunodeficiency virus; HPV, human papillomavirus; LEEP, loop electrosurgical excision 
procedure; VIA, visual inspection with acetic acid.
Note: It is expected that 10 to 15% of the women screened with the CareHPV test and 15 to 20% of those 
screened by VIA will give a positive result (+). Of the women found to have abnormalities when visually 
inspected, 75% are expected to have small precancerous lesions that can be covered by a cryoprobe; 
20% are expected to have large precancerous lesions or lesions in the endocervical canal that cannot be 
covered by a cryoprobe, and 5% are expected to have lesions suggestive of cervical cancer.
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this success rate – and the potential to 
integrate screening for, and treatment 
of, precancerous cervical lesions into 
routine services for maternal and child 
health, sexual and reproductive health, 
and care for patients infected with HIV 
infection – Rwanda chose to focus first 
on cryotherapy and LEEP.
Cryotherapy involves using a cryo-
probe emitting carbon dioxide or nitrous 
oxide to freeze precancerous lesions on 
the cervix. This procedure can generally 
be performed within 15 minutes by a 
trained physician, nurse or midwife at a 
health centre. LEEP – which is primar-
ily used for the removal of large lesions 
that cannot be covered with a cryoprobe 
or the removal of lesions involving the 
endocervical canal – is performed by 
physicians in hospital settings. In this 
procedure, a thin, electrically heated 
wire is used to remove lesions and any 
transformed tissue, after the patient has 
been given local anaesthesia.
Both cryotherapy and LEEP will be 
scaled up for use in the same catchment 
areas and on the same timeline as HPV 
testing, and will be provided for free on 
an outpatient basis. Cryotherapy will be 
available at health centres and hospitals, 
whereas LEEP will only be available in 
hospitals. If a woman requires more 
involved treatment for cervical cancer 
– such as surgery, chemotherapy or 
radiotherapy – she will be immediately 
referred for biopsy and the necessary 
advanced treatment. Although radio-
therapy is not yet possible in the country, 
Rwanda became a member of the Inter-
national Atomic Energy Agency – an es-
sential precursor to constructing an in-
country radiation facility – in September 
2012. As part of the Rwandan Human 
Resources for Health Programme, the 
Faculty of Medicine of the National Uni-
versity of Rwanda has begun a four-year 
residency programme in pathology and 
it is hoped that, in consequence, 12 new 
pathologists will have graduated – and 
many more will be in training – by 2018.
Little palliative care has been avail-
able in Rwanda because of the insuf-
ficient human resources available for 
health care and the many competing 
priorities for funding and advocacy.20 
However, the national strategic plan for 
cervical cancer prevention, care and 
control is part of a larger movement in 
Rwanda that aims to promote palliation. 
As the country moves towards tackling 
noncommunicable diseases – including 
the drafting of a strategic plan for the 
control of such diseases and the care 
of patients with such diseases – it is 
simultaneously strengthening compre-
hensive patient care, including palliative 
and end-of-life care. Rwanda’s National 
Palliative Care Policy was launched in 
April 2011.21 By December 2012, 85% 
of providers at the 42 district hospitals 
in the country had been trained on 
the national guidelines for palliation. 
Morphine was added to the national 
Essential Medicines List and is in the 
process of being included in the sup-
ply chains of the 42 district hospitals 
and the health centres in the hospitals’ 
catchment areas. The health ministry 
is currently exploring the feasibility of 
training up to 30 000 new community 
health workers in the provision of pal-
liative care at the community level for 
patients with HIV infection, cancer and 
other chronic conditions.
Programme costs and 
sustainability
The launching of the first national pro-
gramme for cervical cancer prevention, 
care and control in Africa required a 
commitment to plan for both long-term 
sustainability and a high level of adapt-
ability in a dynamic situation. Merck 
and QIAGEN committed themselves 
to donating to Rwanda and its fund-
ing partners HPV vaccines and DNA 
testing machines and kits, respectively, 
for three-year periods, and to offer 
concessional pricing thereafter. These 
donations have been complemented by 
a range of investments by the Rwandan 
government in additional equipment 
and consumables, building supply chain 
capacity, training and communication 
campaigns.
In May 2013, GAVI announced that 
it would support Rwanda’s national HPV 
vaccination programme after Merck’s 
donation ends in 2014.22 A coalition of 
partners engaged in building Rwanda’s 
cancer response, including the United 
States Centers for Disease Control and 
Prevention, will assist in scaling up 
cervical cancer screening, treatment and 
palliation.23 The Rwandan government 
has committed itself to co-funding these 
activities and expects that investments 
in vaccination and early detection will 
be offset by the prevention of invasive 
cancers and premature deaths.24 The 
results of an in-depth costing analysis 
of vaccination, screening and treatment 
activities will be presented in a future 
article.
Conclusion
Rwanda’s experience shows that – just 
as international funding mechanisms 
for HIV infection, tuberculosis and ma-
laria have been harnessed to strengthen 
primary care – a programme for the 
control of cervical cancer can be used to 
catalyse country investment in compre-
hensive systems of cancer care.25 A new 
partnership with Susan G Komen for 
the Cure that was launched in late 2012 
will target the screening and treatment 
of breast cancer in Rwanda.9 In col-
laboration with development partners, 
the Rwandan Ministry of Health opened 
its first comprehensive cancer centre, at 
Butaro District Hospital, in July 2012. 
An additional ambulatory cancer care 
centre was opened at the hospital in June 
2013. Several of Rwanda’s referral hos-
pitals have maintained cancer registries 
over different periods since the 1990s; a 
national cancer registry initiated in 2011 
is now being scaled up to cover selected 
district hospitals across the country.23
The key lessons learnt during the 
early phases of Rwanda’s cervical cancer 
programme (Box 1) include the value of 
cross-sectoral collaboration and plan-
ning: of engaging development partners, 
the national ministries of finance, gender, 
youth and education, and local govern-
ment; of conducting sustained campaigns 
of communication and social mobiliza-
tion that involve local leaders; of rigor-
ously monitoring vaccination coverage 
over time; and of systematically integrat-
Box 1. Summary of main lessons learnt
•	 It is feasible for low-income countries to integrate cervical cancer prevention, screening 
and treatment into routine women’s health services.
•	 Such integration requires political will, cross-sectoral collaboration and planning, innovative 
partnerships and robust monitoring and evaluation.
•	 With external support and adequate planning, high nationwide coverage rates for HPV 
vaccination and screening for cervical cancer can be achieved within a few years.
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ing routine health services for women 
into the primary-health-care system.
The world now has the tools to 
prevent most cases of cervical cancer 
and most deaths from the disease in the 
coming decades, and these technologies 
will certainly be brought to bear in re-
source-rich countries, where the burden 
of cervical cancer continues to decline.6 
However, if investments are not made in 
delivering on public health’s potential 
to address cervical cancer among the 
poorest populations, inequalities in 
outcome will grow even as the relevant 
technology continues to improve. As a 
pathology of poverty at the convergence 
of infectious and noncommunicable 
diseases, cervical cancer should feature 
prominently in an integrated, post-2015 
development agenda.26
Equitable access to the integrated 
prevention, care and treatment of cervi-
cal cancer should be viewed as a triple 
– epidemiological, economic and moral 
– imperative.27 The cost of inaction is 
massive and untenable. It has been esti-
mated that every five-year delay in scal-
ing up services for cervical cancer vac-
cination alone (not to mention screening 
and treatment) in developing countries 
will cost the lives of up to 2 million 
additional women – many of them of 
reproductive age and actively engaged 
in the workforce.28 Ongoing efforts in 
Rwanda and other countries to monitor 
the incidence of cervical cancer and its 
related mortality, the costs and impact 
of HPV vaccination and screening, and 
treatment outcomes, will help to inform 
global efforts to promote evidence-based 
action against cervical cancer. From 
Rwanda’s perspective, the choice is clear: 
it is time to stop debating whether to act 
and to start fruitful exchanges on how 
best to expand women’s access to pre-
ventive and curative services, optimize 
service quality and ensure programme 
sustainability. ■
Competing interests: None declared.
ملخص
دمج برامج الصحة الشاملة للمرأة يف النظم الصحية: توقي رسطان عنق الرحم ورعايته ومكافحته يف رواندا
الرحم  عنق  رسطان  توقي  عىل  القدرة  ارتفاع  الرغم  عىل  املشكلة 
بني  فتكًا  وأكثرها  شيوعًا  الرسطان  أنواع  أكثر  أنه  إال  وعالجه، 
النساء يف رواندا.
األسلوب عن طريق حشد حتالف متنوع من الرشاكات، أصبحت 
رواندا أول بلد يف أفريقيا يضع وينفذ خطة اسرتاتيجية وطنية لتوقي 
رسطان عنق الرحم وفحصه وعالجه.
املواقع املحلية رواندا - دولة غري ساحلية صغرية يبلغ عدد سكاهنا 
10.4 مليون نسمة وتقع يف رشق أفريقيا - وهي يف وضع جيد يتيح 
هلا مواجهة عدد من األمراض غري السارية ذات ”العبء الثقيل“. 
ونتج عن املقاومة املتكاملة لألمراض املعدية يف البلد انخفاضات 
حادة يف معدل الوفيات املبكرة عىل مدار العقد املنرصم.
ات ذات الصلة يف الفرتة من 2011 إىل 2012، قامت رواندا  التغيرّ
فريوس  لقاح  من  جرعات  الثالث  بكل  فتاة   227246 بتطعيم 
للثالث  التغطية  معدالت  حتقيق  وتم  البرشي.  احلليمي  الورم 
يف   % و96.6   %  93.2 بنسبة  املؤهالت،  الفتيات  بني  جرعات، 
عامي 2011 و2012، عىل التوايل. وبدأت البلد كذلك يف برامج 
التحري والعالج عىل الصعيد الوطني التي استندت عىل الفحص 
باستخدام محض اخلليك، وفحص احلمض  الرحم  لعنق  البرصي 
بالتربيد،  واملعاجلة  البرشي،  احلليمي  الورم  لفريوس  النووي 
من  وعدد  الكهربائية  باجلراحة  العروي  االستئصال  وإج�راء 
خيارات العالج املتقدمة.
الدروس املستفادة ينبغي أن تبدأ البلدان املنخفضة الدخل التعامل 
مع رسطان عنق الرحم عن طريق دمج التوقي والفحص والعالج 
يف اخلدمات الصحية الروتينية للمرأة. ويتطلب ذلك إرادة سياسية 
ورصدًا  مبتكرة  ورشاكات  القطاعات  مجيع  بني  وختطيطًا  وتعاونًا 
املالئم،  والتخطيط  اخلارجي  الدعم  خالل  ومن  قويني.  وتقيياًم 
يمكن حتقيق معدالت تغطية مرتفعة عىل الصعيد الوطني يف تطعيم 




问题 虽然宫颈癌高度可防可治 , 但是对于卢旺达妇女
却是最常见和最致命的癌症。
方法 通过动员多样化的伙伴关系联盟 , 卢旺达成为非
洲第一个制定和实施宫颈癌预防、筛查和治疗国家战
略计划的国家。




相关变化 在 2011–2012 年 , 卢旺达为 227246 名女孩
接种所有三剂人类乳头状瘤病毒 (HPV) 疫苗。在符合
条件的女孩中 , 分别在 2011 年和 2012 年实现三剂疫苗
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Résumé
Intégration de programmes de soins complets pour les femmes dans les systèmes de santé: prévention, traitement et lutte 
contre le cancer du col de l’utérus au Rwanda
Problème Bien qu’il soit possible de le prévenir et de le guérir, le cancer 
du col de l’utérus est le cancer le plus fréquent et le plus mortel chez 
les femmes au Rwanda.
Approche En mobilisant une coalition hétéroclite de partenariats, le 
Rwanda est devenu le premier pays d’Afrique à développer et à mettre 
en œuvre un plan stratégique national pour la prévention, le dépistage 
et le traitement du cancer du col de l’utérus.
Environnement local Le Rwanda, un petit pays enclavé d’Afrique 
orientale, comptant 10,4 millions d’habitants, est bien positionné 
pour s’attaquer à un certain nombre de maladies non transmissibles 
constituant un «lourd fardeau». La réaction intégrée du pays aux 
maladies infectieuses a entraîné une forte diminution de la mortalité 
prématurée au cours de la dernière décennie.
Changements significatifs En 2011-2012, le Rwanda a vacciné 
227 246 jeunes filles avec les trois doses du vaccin contre le virus du 
papillome humain (VPH). Parmi les jeunes filles admissibles, les taux 
d’administration des trois doses ont atteints 93,2% et 96,6% en 2011 
et 2012, respectivement. Le pays a également lancé des programmes 
nationaux de dépistage et de traitement, basés sur l’inspection visuelle 
du col avec de l’acide acétique, le test de dépistage de l’ADN du VPH, 
la cryothérapie, la technique d’excision électrochirurgicale à l’anse et 
différentes options de traitement avancé.
Leçons tirées Les pays à faible revenu devraient commencer à lutter 
contre le cancer du col de l’utérus en intégrant la prévention, le 
dépistage et le traitement dans les services de soins de santé féminins 
de routine. Cela exige une volonté politique, une collaboration et une 
planification intersectorielle, des partenariats innovants, ainsi qu’un suivi 
et une évaluation solides. Avec un soutien externe et une planification 
adéquate, on peut atteindre en quelques années des taux nationaux 
élevés de vaccination contre le VPH et de dépistage du cancer du col 
de l’utérus.
Резюме
Интеграция комплексных программ по охране здоровья женщин в систему здравоохранения: 
профилактика, оказание помощи и борьба с раком шейки матки в Руанде
Проблема Несмотря на наличие эффективных методов по 
профилактике и лечению рака шейки матки, это заболевание 
является одним из самых распространенных видов рака среди 
женщин в Руанде, которое наиболее часто приводит к летальному 
исходу.
Подход Проведя координацию деятельности союзов партнерских 
организаций, Руанда стала первой африканской страной, которая 
разработала и внедрила национальный стратегический план по 
профилактике, выявлению и лечению рака шейки матки.
Местные условия Руанда — небольшая страна с населением 10,4 
млн. человек в Восточной Африке, не имеющая выхода к морю. 
Она занимает выгодное положение для проведения эффективной 
борьбы с неинфекционными заболеваниями, имеющими тяжелые 
последствия. Комплексный подход к проведению борьбы с 
инфекционными заболеваниями в масштабах страны привел к 
резкому снижению преждевременной смертности за последнее 
десятилетие.
Осуществленные перемены На протяжении 2011–2012 
годов в Руанде была проведена вакцинация 227 246 девочек 
всеми тремя дозами вакцины против вируса папилломы 
человека (ВПЧ). Среди отвечающих установленным критериям 
девочек, все три дозы вакцины получили 93,2% и 96,6% из 
них, в 2011 и 2012 годах соответственно. В стране были также 
развернуты общенациональные программы по выявлению и 
лечению этого заболевания, предусматривающие визуальное 
обследование шейки матки с применением уксусной кислоты, 
тестирование на наличие ДНК ВПЧ, криотерапию, процедуры 
электрохирургического удаления петель и различные 
прогрессивные методы лечения.
Выводы Страны с низким уровнем дохода должны приступить 
к решению проблемы заболеваемости раком шейки матки. С 
этой целью необходимо произвести интеграцию профилактики, 
выявления и лечения в стандартную систему медицинского 
обслуживания женщин. Для этого требуется политическая воля, 
межотраслевое взаимодействие и планирование, применение 
инноваций и тщательный контроль наряду с оценкой результатов. 
При наличии внешней поддержки и адекватного планирования, 
высокого уровня внедрения программы по вакцинации от ВПЧ 
в масштабах страны и выявления рака шейки матки можно 
достигнуть в течении нескольких лет.
Resumen
Incorporación de los programas integrales de salud femenina en los sistemas sanitarios: la prevención, la atención y el control 
del cáncer de cuello uterino en Rwanda
Situación El cáncer cervical se puede prevenir y tratar en gran medida; 
aun así, constituye el tipo de cáncer más común y mortal entre las 
mujeres de Rwanda.
Enfoque Rwanda se convirtió en el primer país de África en desarrollar 
e implementar un plan estratégico nacional para la prevención, la 
detección y el tratamiento del cáncer cervical mediante la movilización 
de una coalición heterogénea de asociaciones.
Marco regional Rwanda, un pequeño país sin litoral situado en el 
este de África con una población de 10,4 millones de habitantes, 
está en condiciones de hacer frente a un conjunto de enfermedades 
no transmisibles de «alta carga». La respuesta integral del país a las 
enfermedades infecciosas ha permitido reducir en gran medida la 
mortalidad prematura durante la última década.
Cambios importantes Entre 2011 y 2012, Rwanda vacunó a 227 246 
niñas con las tres dosis de la vacuna contra el virus del papiloma humano 
(VPH). Entre las chicas que cumplían con los requisitos, se alcanzaron 
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tasas de cobertura de las tres dosis del 93,2 % y 96,6 % en 2011 y 2012, 
respectivamente. Asimismo, el país ha puesto en marcha programas de 
detección y tratamiento a nivel nacional, que se basan en la exploración 
visual del cuello uterino con ácido acético, pruebas de ADN del VPH, 
crioterapia, el procedimiento de escisión electroquirúrgica con asa y 
otros tratamientos avanzados.
Lecciones aprendidas Los países con ingresos bajos deben comenzar 
a tratar el cáncer cervical mediante la integración de la prevención, 
la detección y el tratamiento en los servicios rutinarios de salud 
femenina. Ello exige voluntad política, la planificación y la colaboración 
intersectorial, el establecimiento de asociaciones innovadoras, así como 
una evaluación y un seguimiento sólidos. Este objetivo podría alcanzarse 
en pocos años mediante la ayuda externa y la planificación adecuada, 
tasas elevadas de cobertura nacional de vacunación contra el VPH y la 
detección del cáncer de cuello uterino.
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